Jaguar Health, Inc. (JAGX) · Oct 28, 2026 · Share issuance
Six-fold plan expansion — 2,273,154 shares if Proposal 3 passes, versus 378,859 previously
Jaguar Health’s stock plan reserve will rise sixfold after the Series R dividend, preserving a 14% share while expanding potential employee dilution.
Jaguar is shifting its business toward rare-disease development of crofelemer for intestinal-failure indications, after licensing its commercialized products to Future Pak; its stated pipeline goal is an MVID NDA filing in mid-2027. This filing is a capital-structure adjustment, not a clinical or operating milestone. The Series R preferred-stock dividend and its planned five-for-one common-stock conversion were already disclosed, so the new information is how Jaguar is resizing employee-equity capacity around that dilution. 〔0〕
| Plan metric | Before adjustment / prior proposal | After adjustment | Filing reference |
|---|---|---|---|
| Shares available under 2014 Plan | 710 shares; 0.14% | 2,273,154 shares if Proposal 3 passes | (Background; Share Reserve Adjustment) |
| Proposed reserve before adjustment | 378,859 shares; 14% | — | (Proposal 3; Share Reserve Adjustment) |
| Incentive-stock-option limit | 27,333 shares | 163,998 shares | (Share Reserve Adjustment) |
| If Proposal 3 fails | 710 shares | 4,260 shares | (Share Reserve Adjustment) |
The six-fold increase preserves the percentage, not the absolute dilution. Jaguar says the reserve should remain approximately 14% of fully diluted shares after the Series R conversion, but that requires expanding the authorization from 378,859 shares to 2,273,154 if shareholders approve Proposal 3. 〔1〕 That is mechanically understandable after the share-count expansion, but it also creates a much larger pool of shares that could eventually be issued as compensation.
The immediate business impact is limited, but the governance signal is meaningful. The filing does not issue the 2.27 million shares, improve funding, or advance crofelemer development; it keeps the equity-incentive plan scaled to the enlarged capitalization. The six-fold reset is therefore partly known through the previously announced Series R transaction, while the exact size of the refreshed reserve is new. 〔2〕
Bottom line: This is mostly a mechanical proxy update, but it confirms that Jaguar’s post-Series R capital structure will support a substantially larger potential equity pool. It matters for dilution and shareholder voting, not for the underlying rare-disease program itself.
Series R conversion, November 2
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!